Regulatory aspects of vaccine development

M14

Course Goals 

This two-day interactive training workshop on vaccine development will introduce participants to planning a regulatory strategy for vaccines with emphasis on the early phases of development. Day 1 will focus on prophylactic vaccines while day 2 will focus on cancer vaccines. The workshop will be designed based on the current bottlenecks and upcoming innovative approaches while planning a regulatory strategy.

Timeline 

Application Deadline:
15 December 2021

Course Dates:
21-22 March, 2022

Organiser

The European Infrastructure for Translational Medicine (EATRIS)

Amsterdam, The Netherlands

Participant Nr.: 20

Contact

Lauranne Duquenne lauranne.duquenne@eatris.eu

Course content

The course is designed for professionals working on vaccine development who are in need of an introduction to the regulatory issues associated with the field. Day 1 will focus on prophylactic vaccines, including lectures and case studies on how to navigate the regulatory maze and how to plan a regulatory strategy, preclinical and Phase I-II of vaccine development, how to prepare a dossier for Medicine Agencies, CMC development. Day 2 will focus on cancer vaccines, with an introduction to the scientific part to understand the regulatory part better.”

Learning Outcomes

Learn how to plan a regulatory strategy from the early phases of development and prepare a well-organised dossier in a changing environment.

Who should apply

Vaccine developers and European researchers from industry and academia.

Minimal requirements

NA

Accommodation

Accommodation: the course will be held in Amsterdam, The Netherlands (exact location to be confirmed). 1 hotel night, 2 lunches and 1 dinner included. Travel costs are not included.

Comments

NA

Weblink

NA

How to apply>>

Kindly note that not all courses are open for application submission, check open calls to know which for which courses you can apply for at the moment.


Be the first to know about the upcoming application calls, follow European Vaccine Initiative on Twitter and LinkedIn or subscribe to TRANSVAC Newsletter